Contributions
Abstract: 197
Type: Oral
Comorbidity is increasingly recognized to be common in multiple sclerosis (MS). It is a major concern in the care of patients with MS and may be associated with the clinical phenotype of the disease. Physical and psychiatric comorbidity may also impact timely diagnosis, disability progression and other outcomes. "Vascular" comorbidities, including diabetes, hypertension, hyperlipidemia and ischemic heart disease, are among the most common comorbidities in MS, and increase in frequency with age. Vascular comorbidity affects a broad range of outcomes in MS ranging from disability progression to mortality to quality of life to responses to fatigue management programs. The health care team needs to develop strategies to prevent and manage these comorbidities effectively and minimize their adverse impact on outcomes.
Disclosure: Ruth Ann Marrie receives research funding from: Canadian Institutes of Health Research, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, National Multiple Sclerosis Society, Rx & D Health Research Foundation, and has conducted clinical trials funded by Sanofi-Aventis.
Abstract: 197
Type: Oral
Comorbidity is increasingly recognized to be common in multiple sclerosis (MS). It is a major concern in the care of patients with MS and may be associated with the clinical phenotype of the disease. Physical and psychiatric comorbidity may also impact timely diagnosis, disability progression and other outcomes. "Vascular" comorbidities, including diabetes, hypertension, hyperlipidemia and ischemic heart disease, are among the most common comorbidities in MS, and increase in frequency with age. Vascular comorbidity affects a broad range of outcomes in MS ranging from disability progression to mortality to quality of life to responses to fatigue management programs. The health care team needs to develop strategies to prevent and manage these comorbidities effectively and minimize their adverse impact on outcomes.
Disclosure: Ruth Ann Marrie receives research funding from: Canadian Institutes of Health Research, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, National Multiple Sclerosis Society, Rx & D Health Research Foundation, and has conducted clinical trials funded by Sanofi-Aventis.